ANGIOTENSIN II TYPE-1 RECEPTOR (AT1R) DISTRIBUTION IN BPH, HIGH GRADE PIN AND ADENOCARCINOMA OF THE PROSTATE

Objective: The aim of the study was to detect the differences in number and the distribution of angiotensin II type-1 receptor (AT1R) in BPH, high grade PIN, and adenocarcinoma of the prostate. Material & method: A prospective study was performed in RSHS, in collaboration with the Department of...

Full description

Saved in:
Bibliographic Details
Published inJurnal urologi Indonesia = Indonesian journal of Urology Vol. 17; no. 2
Main Authors Septiadi, Isdianto, Sugandi, Suwandi, Noegroho, Bambang S, Tjahjodjati, Tjahjodjati, Safriadi, Ferry, Siregar, Safendra, Adriansjah, Ricky, Adi, Kuncoro, Sihombing, Aaron T, Pramod, Sawkar V, Nasution, Ramlan, Hernowo, Betthy S
Format Journal Article
LanguageEnglish
Published IKATAN AHLI UROLOGI INDONESIA 01.11.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective: The aim of the study was to detect the differences in number and the distribution of angiotensin II type-1 receptor (AT1R) in BPH, high grade PIN, and adenocarcinoma of the prostate. Material & method: A prospective study was performed in RSHS, in collaboration with the Department of Anatomical Pathology. Prostate samples were taken by TUR of the prostate, and then divided into 5 groups. They were BPH, high grade PIN, adenocarcinoma of the prostate in 3 difference grades (well, moderate, and poorly differentiated). Kidney tissue for control. Immunohistochemical staining was done to determine the angiotensin II type-1 (AT1R) receptor distribution as primary antibody used was mouse monoclonal antibody AT1 (TONI-1): sc-57036, Santa Cruz Biotechnology Inc., CA. Results: Angiotensin II type-1 receptor was found in material of BPH, high grade PIN and adenocarcinoma of the prostate. The number and distribution of the receptors were not different. Conclusion: There are no significant differences in number and distribution of angiotensin II type-1 receptor on BPH, high grade PIN, and adenocarcinoma of the prostate.
ISSN:0853-442X
2355-1402
DOI:10.32421/juri.v17i2.348